David A. Siegel Poseida Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 37,400 shares of PSTX stock, worth $354,552. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37,400Holding current value
$354,552% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding PSTX
# of Institutions
98Shares Held
38.5MCall Options Held
377KPut Options Held
22.2K-
Pentwater Capital Management LP Naples, FL5.98MShares$56.6 Million0.18% of portfolio
-
Black Rock Inc. New York, NY4.91MShares$46.5 Million0.0% of portfolio
-
Silverarc Capital Management, LLC3.69MShares$35 Million2.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.66MShares$34.7 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.19MShares$20.8 Million0.0% of portfolio
About Poseida Therapeutics, Inc.
- Ticker PSTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 85,775,600
- Market Cap $813M
- Description
- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...